Premium
Ursodeoxycholic acid protects cardiomyocytes against cobalt chloride induced hypoxia by regulating transcriptional mediator of cells stress hypoxia inducible factor 1α and p53 protein
Author(s) -
Mohamed Anis Syamimi,
Hanafi Noorul Izzati,
Sheikh Abdul Kadir Siti Hamimah,
Md Noor Julina,
Abdul Hamid Hasani Narimah,
Ab Rahim Sharaniza,
Siran Rosfaiizah
Publication year - 2017
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3303
Subject(s) - cardioprotection , viability assay , ursodeoxycholic acid , pertussis toxin , agonist , chemistry , pharmacology , intracellular , calcium in biology , hypoxia (environmental) , microbiology and biotechnology , receptor , biology , cell , biochemistry , medicine , g protein , ischemia , organic chemistry , oxygen
In hepatocytes, ursodeoxycholic acid (UDCA) activates cell signalling pathways such as p53, intracellular calcium ([Ca 2+ ] i ), and sphingosine‐1‐phosphate (S1P)‐receptor via Gα i ‐coupled‐receptor. Recently, UDCA has been shown to protect the heart against hypoxia‐reoxygenation injury. However, it is not clear whether UDCA cardioprotection against hypoxia acts through a transcriptional mediator of cells stress, HIF‐1α and p53. Therefore, in here, we aimed to investigate whether UDCA could protect cardiomyocytes (CMs) against hypoxia by regulating expression of HIF‐1α, p53, [Ca 2+ ] i , and S1P‐Gα i ‐coupled‐receptor. Cardiomyocytes were isolated from newborn rats (0‐2 days), and hypoxia was induced by using cobalt chloride (CoCl 2 ). Cardiomyocytes were treated with UDCA and cotreated with either FTY720 (S1P‐receptor agonist) or pertussis toxin (PTX; Gα i inhibitor). Cells were subjected for proliferation assay, beating frequency, QuantiGene Plex assay, western blot, immunofluorescence, and calcium imaging. Our findings showed that UDCA counteracted the effects of CoCl 2 on cell viability, beating frequency, HIF‐1α, and p53 protein expression. We found that these cardioprotection effects of UDCA were similar to FTY720, S1P agonist. Furthermore, we observed that UDCA protects CMs against CoCl 2 ‐induced [Ca 2+ ] i dynamic alteration. Pharmacological inhibition of the Gα i ‐sensitive receptor did not abolish the cardioprotection of UDCA against CoCl 2 detrimental effects, except for cell viability and [Ca 2+ ] i . Pertussis toxin is partially effective in inhibiting UDCA protection against CoCl 2 effects on CM cell viability. Interestingly, PTX fully inhibits UDCA cardioprotection on CoCl 2 ‐induced [Ca 2+ ] i dynamic changes. We conclude that UDCA cardioprotection against CoCl 2 ‐induced hypoxia is similar to FTY720, and its actions are not fully mediated by the Gα i ‐coupled protein sensitive pathways. Ursodeoxycholic acid is the most hydrophilic bile acid and is currently used to treat liver diseases. Recently, UDCA is shown to have a cardioprotection effects; however, the mechanism of UDCA cardioprotection is still poorly understood. The current data generated were the first to show that UDCA is able to inhibit the activation of HIF‐1α and p53 protein during CoCl 2 ‐induced hypoxia in cardiomyocytes. This study provides an insight of UDCA mechanism in protecting cardiomyocytes against hypoxia.